In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
about
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesPertuzumab and breast cancer: another piece in the anti-HER2 puzzle.Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancerDual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsT-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy.Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancerTubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with TrastuzumabClass III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxelClinicopathologic study in uterine cancer.Emerging therapeutic targets in endometrial cancer.Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.Endometrial cancer: redefining the molecular-targeted approach.Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.Pertuzumab for the treatment of breast cancer: a safety review.A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli.Endometrial Carcinoma: Specific Targeted Pathways.Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23).Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.Structural basis of a novel heterodimeric Fc for bispecific antibody production.Dual "mAb" HER family blockade in head and neck cancer human cell lines combined with photon therapy.Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers.Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.Complement as a Biological Tool to Control Tumor GrowthDevelopment and Analytical Validation of a BT-474 Anti-Proliferation Assay Targeting HER2
P2860
Q26822730-60AE11D2-12CF-4F7D-880A-5BDF84A5304CQ33364587-2E897F26-9F3D-402D-8CC2-D349B6FB5497Q33755476-32EDD5D5-B53F-4180-9F1F-4522394F3CA6Q34055089-1846F9B9-45BA-44CB-8105-905BA45E558FQ34126568-DD850B6B-D0DD-4F05-9763-6595D69514D5Q34253625-AE85B7E4-B9B6-4F67-8A1D-B4F0ECFB5FB7Q34634149-9D9597B9-8B32-42DE-A09F-5142C2AD4CC5Q34714574-FF8BC715-FF68-48DA-A657-29758C431165Q34998509-8E032625-D9A5-40DE-8DCF-1CDE62CA265DQ35027806-39584B1E-D3DC-446A-A832-F52F001DD579Q35083850-A010EFCF-1829-4072-B826-A0BD5A3D15C9Q35174196-CC1361C5-37AA-42AD-BCC8-A8477F328A7BQ35527141-DE546D11-9D90-4229-B8B8-11B7626DCD2DQ35927368-4452BD7E-E991-4D17-8F5E-CBD9F1576B56Q36004109-DC581045-4043-43B9-A067-3C56CE3168D1Q36103790-6269B270-EB8E-4E61-92B5-6A611C6CDD32Q36821263-EFE7E99D-D009-42E3-B6B1-C45D717C738CQ36980135-2A50B13E-2D23-456D-9144-8A919B7F4A25Q37148772-153288E8-B537-4523-AA9D-68CD88F00937Q37625835-278B058E-FCD1-4969-9B4A-3D9BE7110077Q37709899-A0EC7C43-8F25-4093-884D-B5EB439C0E3AQ37827340-B2F77029-2A21-4835-A084-5FB231B7079EQ38385131-C8C40434-1847-4E76-A860-6A6A0D5CC5D8Q38454955-A9F30FC7-A2D1-4F22-8C60-13449A7AAECBQ38708134-E86F9BD6-1136-40FB-A932-A8DE590242A8Q38776876-A223B8A2-87FF-4364-80D8-4B5F1B6E7FCBQ38995713-62562A48-70ED-4461-95E2-AFDA74BEFF25Q39011393-2BDDC883-1D24-4C6D-8C4F-F7D8929B054DQ39026766-CE08162D-E2D5-4589-B452-F8C109758A39Q39290163-0C93B20A-4EB6-4749-A812-8A102570FC6AQ39447473-AC365F32-2A63-4512-BBA7-23A2608EEE8FQ41612592-2792973E-37EE-4AA9-A1AC-7BAACB19C3A7Q42120714-ADADDF43-DA03-401C-9D8E-8CB0419AB0DDQ45904308-5E43A071-EC88-4829-954D-611442397E9AQ50027073-28F427D6-E818-446D-9FFA-1FC1B4AF3BC2Q50113702-9F6552B4-C4B6-44E5-A93D-BF74B7E96F32Q52297317-F07DBBBE-4AE6-4C74-86CF-808D53FD7866Q55015029-00F9CCA1-DE27-4B66-8F04-1AF8E5BE3E2BQ57492005-A8C58ED1-B32D-4637-91EA-D381B64B1018Q58126050-ADDB767D-CE68-458E-B4F3-574C6A78BA53
P2860
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
In vitro activity of pertuzuma ...... rous papillary adenocarcinoma.
@ast
In vitro activity of pertuzuma ...... rous papillary adenocarcinoma.
@en
type
label
In vitro activity of pertuzuma ...... rous papillary adenocarcinoma.
@ast
In vitro activity of pertuzuma ...... rous papillary adenocarcinoma.
@en
prefLabel
In vitro activity of pertuzuma ...... rous papillary adenocarcinoma.
@ast
In vitro activity of pertuzuma ...... rous papillary adenocarcinoma.
@en
P2093
P2860
P4510
P356
P1476
In vitro activity of pertuzuma ...... rous papillary adenocarcinoma.
@en
P2093
A D Santin
D-A Silasi
F A Tavassoli
F Casagrande
K El-Sahwi
M Abu-Khalaf
M Cargnelutti
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605448
P407
P577
2009-11-17T00:00:00Z
P5875
P6179
1011011108